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Whether thyroid replacement therapy can trigger cardiac 
arrhythmias in patients with hypothyroidism is not known. 
In this prospective study, 24 h ambulatory electrocardio- 
graphic (ECG) monitoring was used to assess the frequency 
of atria1 and ventricular premature beats in 25 patients 
with hypothyroidism (5 men and 20 women, aged 56 f 3 
years) before and 3.5 + 0.5 months (mean + SEM) after 
thyroid replacement therapy. Plasma thyroid-stimulating 
hormone was 73.6 f 12.3 and 3.1 f 0.6 @/ml and free 
thyroxine index was 2.4 + 0.4 and 9.8 f 0.9 pg/lOO ml at 
baseline and after thyroid replacement therapy, respec- 
tively. 
The frequency of ventricular premature beats was not 
affected by thyroid replacement therapy (from 273 5 221 at 
baseline to 352 f 235 beats/24 h after therapy), even in 
patients with frequent baseline arrhythmias. In contrast, 
Hypothyroidism is classically associated with bradyarrhyth- 
mias, such as sinus bradycardia, and rarely atrioventricular 
(AV) block (l-7). Tachyarrhythmias and extrasystoles are 
infrequent in patients with hypothyroidism. Only rare in- 
stances of “torsades de pointe” have been described (8-l 1) 
in patients with severe hypothyroidism. This low incidence 
of tachyarrhythmias and extrasystoles has led to the belief 
that hypothyroidism may have some antiarrhythmic proper- 
ties (12,131, although this has not been well documented. If 
this assumption is true, one might expect an increased 
incidence of arrhythmias during thyroid replacement therapy 
in patients with hypothyroidism, particularly in those with 
some arrhythmias in the hypothyroid state. Furthermore, 
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the frequency of atrial premature beats was slightly in- 
creased after thyroid replacement therapy (from 47 2 17 to 
279 + 197 beats/24 h), largely as a result of changes seen in 
three patients. No patient developed new onset of sustained 
ventricular or supraventricular arrhythmias. Average, 
basal and maximal heart rates during ECG monitoring 
increased significantly after thyroid replacement therapy 
(average 72 + 2 to 80 + 2; basal 64 + 2 to 70 rt 2; maximal 
114 f 3 to 130 f 3 beats/min, respectively, p < 0.001). 
In conclusion, thyroid replacement therapy is safe in 
patients with common benign cardiac arrhythmias, and 
does not trigger an increase in arrhythmia frequency except 
in rare patients with baseline atria1 premature beats. It is, 
however, associated with an increase in basal, average and 
maximal heart rates. 
(J Am Co11 Cardiol1989;14:999-1002) 
the effect of thyroid replacement therapy on heart rate has 
never been assessed in humans. 
In this prospective study, we used 24 h electrocardio- 
graphic (ECG) monitoring to assess whether thyroid replace- 
ment therapy increased the frequency of atria1 and ventric- 
ular arrhythmias in 25 patients with hypothyroidism. In 
addition, the impact of thyroid replacement therapy on 
basal, average and maximal heart rates was evaluated. 
Methods 
Study patients. Twenty-five patients, 5 men and 20 
women, aged 30 to 80 years (mean f SEM 56 t 3 years) with 
primary hypothyroidism were enrolled in this study from 
July 1986 to June 1988. Hypothyroidism was diagnosed with 
use of standard thyroid function tests. Eleven patients had a 
history of cardiovascular disease: five had systemic hyper- 
tension, four had coronary artery disease, one had hyper- 
trophic cardiomyopathy and one had undergone valve re- 
placement for aortic stenosis. No patient had signs of left 
ventricular failure (third heart sound or pulmonary rales, or 
both). All patients had sinus rhythm, except two who had 
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chronic atria1 fibrillation. The protocol was approved by the 
University of California-San Diego Medical Center Human 
Subjects Committee, and all patients gave informed consent. 
Thyroid function tests. Plasma thyroxine, thyroid- 
stimulating hormone, triiodothyronine resin uptake and free 
thyroxine index were measured and calculated by standard 
methods (14-16). 
Ambulatory electrocardiographic monitoring. Twenty- 
four hour ambulatory ECG monitoring was obtained for each 
patient before and after thyroid replacement therapy. All 
tapes were analyzed on a Del Mar Avionics Innovator 
scanner (model 7.50) by the same operator, who had no 
knowledge of the status of the thyroid replacement therapy. 
Average heart rate was computed by the scanner after 
checking the whole tape for any motion artifact. Similarly, 
basal heart rate was determined by averaging up to 6 h of 
steady heart rate during sleep hours. Maximal heart rate was 
also computed by using a 16 beat sliding average after 
checking for motion artifacts. Ventricular and atria1 arrhyth- 
mias were counted by the scanner, in learning mode, to 
directly control the accuracy of the count. Heart rate com- 
putation could not be obtained in four patients as a result of 
inadequate calibration of the tapes in two and the presence 
of atria1 fibrillation in two. 
Treatment protocol. Each patient was studied at baseline 
and at 3 t 0.5 months after the initiation of thyroid replace- 
ment therapy. All medications except thyroxine were kept 
constant during the study period. Two patients were taking a 
beta-adrenergic blocking agent for their hypertension, two 
were taking digoxin, one was taking verapamil and one was 
taking flecainide for severe palpitation. The dose of thyrox- 
ine used ranged from 37.5 to 200 pg/day (mean 117.5 +- 10). 
The starting dose was 50 pg/day, which was increased 
stepwise, generally in increments of 50 pg every 2 weeks, to 
a maximum of 100 to 150 pg/day, if this dose was well 
tolerated. No patient reported significant cardiac symptoms 
such as angina pectoris or palpitation after replacement 
therapy. 
Statistics. Comparisons of variables measured before and 
after thyroid replacement therapy were made with use of the 
paired Student’s t test. Values are expressed as mean values 
? SEM. 
Results 
At baseline, patients with hypothyroidism had a de- 
creased plasma free thyroxine index (2.4 2 0.4 pg/lOO ml) 
and increased plasma thyroid-stimulating hormone (73.6 2 
12.3 $J/ml). After 3.5 + 0.5 months of thyroid replacement 
therapy, thyroid function test results were in the euthyroid 
range (free thyroxine index 9.8 2 0.9 pg/lOO ml; thyroid- 
stimulating hormone 3.1 -t 0.6 pU/ml). 
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Figure 1. Number of atria1 premature beats (APB’s) recorded during 
24 h ambulatory electrocardiographic monitoring before (Hypo) 
(mean 47 ? 17) and after (Euth) (mean 279 ? 197) thyroid replace- 
ment therapy in 25 patients with hypothyroidism. 
Twenty-four hour electrocardiographic monitoring (Fig. 1 
to 3). There was a small but statistically insignificant in- 
crease in the frequency of atria1 premature beats after 
thyroid replacement therapy (from 47 + 17 to 279 ? 197 
beats/24 h) that was mainly due to changes seen in three 
patients (Fig. 1). Seven patients with hypothyroidism had a 
total of 27 runs of supraventricular tachycardia (ranging from 
3 to 41 beats) at a maximal rate of 123 to 173 beats/min (mean 
148 2 7). After thyroid replacement therapy, eight patients 
had a total of 38 runs of supraventricular tachycardia 
(ranging from 3 to 66 beats) at a maximal rate of 101 to 192 
beats/min (mean 154 + 12). No significant change in the 
frequency of ventricular premature beats after thyroid re- 
placement therapy was seen (from 273 ? 221 to 352 + 235 
beats/24 h) (Fig. 2) and no patient developed malignant 
arrhythmias such as ventricular tachycardia. 
Figure 2. Number of ventricular premature beats (VPB’s) recorded 
during 24 h ambulatory electrocardiographic monitoring before 
(Hypo) (mean 273 k 221) and after (Euth) (mean 352 k 235) thyroid 
replacement therapy in 25 patients with hypothyroidism. 
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Figure 3. Basal, average and maximal heart rates recorded during 
24 h ambulatory electrocardiographic monitoring in patients studied 
before (Hype) and after (Euth) thyroid replacement therapy. 
Only one patient who uas receiving no medication had 
frequent intermittent second degree atrioventricular block 
with hypothyroidism. After thyroid replacement therapy, 
the block was still intermittently present, but to a much 
lesser extent. 
Basal heart r&e (64 ? 2 to 70 i 2 beatsimin. p < 0.001) 
and average heart rate (72 2 2 to 80 ? 2 beatsimin, p < 
0.001) were significantly higher after thyroid replacement 
therapy (Fig. 3). but the largest increase was seen for 
maximal heart rate reached during a 24 h period (114 ? 3 to 
130 i- 3 beatsimin. p < 0.001). 
Discussion 
Our study suggests that, overall, thyroid replacement 
therapy has a minor impact on the frequency of benign atria1 
and ventricular arrhythmias in patients. This finding also 
suggests that thyroid replacement therapy is generally safe in 
patients with common benign arrhythmias. and that hy- 
pothyroidism may not be protective against these arrhyth- 
mias. Furthermore, during a 24 h period, small increases in 
basal or average heart rate and more prominent increases in 
maximal heart rate are observed after thyroid replacement 
therapy. 
Role of hypothyroidism in arrhythmias. That hypothy- 
roidism might be protective against arrhythmias, including 
ventricular premature beats. is suggested by clinical obser- 
vations and supported by few findings (12,13). In an animal 
model of ventricular fibrillation, hypothyroidism was shown 
(17) to increase the fibrillatory threshold of the ventricles. 
The prolongation of the corrected QT (QTc) interval seen in 
patients with hypothyroidism (18) is similar to that seen in 
patients taking antiarrhythmic drugs such as the type III 
agents. Furthermore, the action of amiodarone (a potent 
type III antiarrhythmic drug) on the frequency of premature 
ventricular beats seems to parallel its blocking effect on the 
peripheral metabolism of thyroid hormones, suggesting that 
hypothyroidism at the tissue level may have some antiar- 
rhythmic properties (19). On the other hand, we recently 
showed (20) that giving triiodothyronine to patients with 
benign ventricular arrhythmias suppressed by amiodarone 
does not reverse its antiarrhythmic efficacy. Our present 
findings also do not support a major antiarrhythmic effect of 
hypothyroidism. at least in patients with benign atria1 and 
ventricular arrhythmias. 
Thefindings of an increased heart rate and a concomitant 
increase in the frequency of atria1 premature beats in a few 
prrtients after thyroid replacement therapy support the gen- 
eral concept that the atria are more sensitive than the 
ventricles to the action of thyroid hormones (12,13,21,22). 
This view is also suggested by the well known increased 
incidence of atrial arrhythmias, including atrial fibrillation, in 
patients with hyperthyroidism (1,21,22). Such a preferential 
effect of thyroid hormones at the sinoatrial level may be 
mediated by a direct effect of thyroid hormones on sinoatrial 
transmembrane potentials (12,13). However, it could also be 
mediated by an increased cardiac sensitivity to catechol- 
amines, as has been shown in animals (23-25) and more 
recently in humans (unpublished data). 
Limitations. Most of our patients had moderate clinical 
hypothyroidism and no severe ischemic heart disease. It is 
possible that a more profound degree of hypothyroidism may 
have more significant effects on arrhythmias than those 
found in our study. Furthermore, we cannot exclude the 
possibility that thyroid replacement therapy might have 
some deleterious effect in patients with very frequent pre- 
mature atrial or ventricular beats, malignant arrhythmias 
such as ventricular tachycardia or fibrillation or severe 
underlying ischemic heart disease. However, we have 
shown that thyroid replacement therapy in patients with 
hypothyroidism with the most common clinical arrhythmias 
(atrial and ventricular premature beats) does not produce a 
clinically significant worsening of these arrhythmias. 
We thank Ana Hefty for expert assistance in the preparation of the manu- 
script. We also thank Wolfgang Dillmann, MD for guidance. 
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